Non human animal model for ulcerative colitis and its main complications
AssigneeInstitut National De La Sante Et De La Recherche Medicale (Inserm)
InventorsEric Ogier-Denis, Xavier Treton, Fanny Daniel, Cecile Guichard, Eric Pedruzzi, Yoram Bouhnik, Yann Harnoy
Life of this patent
Estimating the term…
Abstract
The present invention relates to a non human model animal for ulcerative colitis and its main complications such as primary sclerosing cholangitis and colorectal cancer. More particularly, the present invention relates to a transgenic non human animal model for ulcerative colitis and its main complications such as primary sclerosing cholangitis, and colorectal cancer comprising a targeted disruption in the IL10 and NOX1 genes so that IL10 and NOX1 are not expressed in said animal.
Claims10
A transgenic non human animal model for ulcerative colitis and its main complications comprising a targeted disruption in the Interleukin 10 (IL10) and NADPH-oxidase1 (NOX1) genes so that IL10 and NOX1 are not expressed in said animal.
A method for producing a transgenic non human animal model for ulcerative colitis and its main complications, comprising cross-breeding a knock-out animal for IL10 with a knock-out animal for NOX1.
A method for screening a candidate compound for use as a drug for the treatment or prevention of ulcerative colitis and/or its main complications comprising i) administering the candidate compound to a transgenic non human animal model comprising a targeted disruption in the Interleukin 10 (IL10) and NADPH-oxidase1 (NOX1) genes so that IL10 and NOX1 are not expressed in said animal, ii) characterizing the phenotype of the non human animal model after the administration of the candidate compound and iii) positively selecting the candidate compound that reverses or delay delays the phenotype of the non human animal model.
Dependencies are inferred from the claim text.